PNT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Dec 2023 @ 16:00):

Stats
Today's Volume	3.29M
Average Volume	3.85M
Market Cap	1.33B
EPS	$0 ( 2024-03-25 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	11.36
ATR14	$0.322 (2.58%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-26	Goodman Jonathan R.	Sell	41 872	Common Stock
2023-12-27	Goodman Jonathan R.	Sell	35 872	Stock Option (Right to Buy)
2023-12-27	Goodman Jonathan R.	Sell	25 000	Stock Option (Right to Buy)
2023-12-27	Goodman Jonathan R.	Sell	25 614	Stock Option (Right to Buy)
2023-12-27	Goodman Jonathan R.	Sell	44 749	Stock Option (Right to Buy)

INSIDER POWER
-77.78
Last 96 transactions
Buy: 3 517 450 \| Sell: 10 366 533

Volume Correlation

Long: 0.24 (neutral)

Short: -0.64 (weak negative)

Signal:(35.382) Neutral

POINT Biopharma Global Correlation

10 Most Positive Correlations
RCM	0.813
LUNG	0.806
TTWO	0.805

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

POINT Biopharma Global Correlation - Currency/Commodity

0.59
( weak )

0.60
( weak )

0.71
( moderate )

-0.65
( moderate negative )

-0.39
( neutral )

-0.49
( neutral )

POINT Biopharma Global Financials

Annual	2022
Revenue:	$226.58M
Gross Profit:	$226.58M (100.00 %)
EPS:	$1.040

Q3	2023
Revenue:	$2.79M
Gross Profit:	$2.79M (100.00 %)
EPS:	$-0.230

Q2	2023
Revenue:	$4.87M
Gross Profit:	$4.87M (100.00 %)
EPS:	$-0.240

Q1	2023
Revenue:	$9.46M
Gross Profit:	$9.46B (100 000.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

POINT Biopharma Global

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.